Your browser doesn't support javascript.
loading
Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
Hirai, Yoji; Sakurai, Jun; Yoshida, Shiho; Kikuchi, Takashi; Mitsuhashi, Toshiharu; Miyake, Tomoko; Fujimura, Taku; Abe, Riichiro; Fujikawa, Hiroki; Boki, Hikari; Suga, Hiraku; Shibata, Sayaka; Miyagaki, Tomomitsu; Shimauchi, Takatoshi; Kiyohara, Eiji; Kawakami, Yoshio; Morizane, Shin.
Afiliación
  • Hirai Y; Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Sakurai J; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Yoshida S; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Kikuchi T; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Mitsuhashi T; Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Miyake T; Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Fujimura T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Abe R; Department of Dermatology, Niigata University, Niigata, Japan.
  • Fujikawa H; Department of Dermatology, Niigata University, Niigata, Japan.
  • Boki H; Department of Dermatology, Tokyo University, Tokyo, Japan.
  • Suga H; Department of Dermatology, Tokyo University, Tokyo, Japan.
  • Shibata S; Department of Dermatology, Tokyo University, Tokyo, Japan.
  • Miyagaki T; Department of Dermatology, Tokyo University, Tokyo, Japan.
  • Shimauchi T; Department of Dermatology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Kiyohara E; Department of Dermatology, Osaka University, Osaka, Japan.
  • Kawakami Y; Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Morizane S; Department of Dermatology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
J Dermatol ; 51(8): 1037-1049, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38874430
ABSTRACT
Brentuximab vedotin (BV), a conjugate of anti-CD30 antibody and monomethyl auristatin E, has emerged as a promising treatment option for refractory CD30+ mycosis fungoides (MF) and primary cutaneous anaplastic large-cell lymphoma (pcALCL). BV has been shown to be safe and effective in treating Hodgkin's lymphoma and peripheral T-cell lymphoma. This multicenter, prospective, single-arm phase I/II study evaluated the efficacy of BV in Japanese patients with CD30+ cutaneous lymphomas, namely CD30+ cutaneous T-cell lymphoma. Participants were divided into two groups those with CD30+ MF or pcALCL (cohort 1, n = 13) and those with CD30+ lymphoproliferative disorders other than those in cohort 1 (cohort 2, n = 3). The studied population included the full analysis set (FAS), modified FAS (mFAS), and safety analysis set (SAF). These sets were identified in cohorts 1 and 1 + 2 and labeled FAS1 and FAS2, mFAS1 and mFAS2, and SAF1 and SAF2, respectively. Each treatment cycle lasted 3 weeks, and BV was continued for up to 16 cycles after the third cycle based on treatment response. The primary endpoint was the 4-month objective response rate (ORR4) determined by the Independent Review Forum (IRF). ORR4 was 69.2% for FAS1 and 62.5% for FAS2 (P < 0.0001). Secondary endpoints of ORR, assessed using the global response score (53.8% in FAS1) and modified severity-weighted assessment tool (62.5% in FAS1), using the IRF, provided results comparable to the primary findings. The incidence of ≥grade 3 adverse events (≥15%) in SAF1 was peripheral neuropathy in three patients (23%) and fever and eosinophilia in two patients (15%). In conclusion, BV showed favorable efficacy, tolerability, and safety profile in Japanese patients with relapsed or refractory CD30+ primary cutaneous T-cell lymphoma. The trial was registered with University Hospital Medical Information Network Clinical Trials Registry, Japan (protocol ID UMIN000034205).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Antígeno Ki-1 / Brentuximab Vedotina Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Antígeno Ki-1 / Brentuximab Vedotina Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido